More Information About - Ostovit D 40000 IU Cap. - 40000 IU
Description
Generic Name
Cholecalciferol (Vit. D3)
Precaution
People with the following conditions should exercise caution when considering taking vitamin D supplements:
High blood Calcium or Phosphorus level
Heart problems
Kidney disease
Vitamin D must be taken with adequate amounts of both Calcium and Magnesium supplementation. When Calcium level is low (due to insufficient vitamin D and calcium intake), the body activates the parathyroid gland, which produces PTH (parathyroid hormone). This hormone kick starts vitamin D hormone production and assists removal of Calcium from the bones to be used in more important functions such as neutralizing body acidity.
Lactation: Drug is distributed into breast milk; use with caution
Indication
Osteoporosis, Hypoparathyroidism, Rickets, Osteomalacia,Vitamin D Deficiency, Pseudohypoparathyroidism, Familial hypophosphatemia
Contra Indication
Colecalciferol is contraindicated in all diseases associated with hypercalcaemia. It is also contraindicated in patients with known hypersensitivity to Colecalciferol (or medicines of the same class) and any of the constituent excipients. Colecalciferol is contraindicated if there is evidence of vitamin D toxicity.
Dose
N/A
Side Effect
Generally all nutritional supplements are considered to be safe and well tolerable. However, few side-effects can generally occur including hypercalcaemia syndrome or Calcium intoxication (depending on the severity and duration of hypercalcaemia), occasional acute symptoms include anorexia, headache, dry mouth, nausea, vomiting, abdominal pain or stomach ache and constipation with the administration of Colecaciferol.
Pregnancy Category
Name :
A
Description
Adequate and well-controlled human studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).
Mode of Action
Vitamin D3 is a fat-soluble sterol. It is necessary for the regulation and regulation of calcium and phosphate homoeostasis and bone mineralisation. Vitamin D is also essential for healthy bones as it aids in Calcium absorption from the GI tract. In addition to this it stimulates bone formation.
Interaction
Increased risk of hypercalcaemia if given with thiazide diuretics, calcium or phosphate. Antiepileptics (e.g. carbamazepine, phenobarbitone, phenytoin & primidone) may increase vitamin D requirements. Rifampicin & isoniazid may reduce efficacy of vitamin D. Corticosteroids may counteract the effect of vitamin D. Digoxin or any cardiac glycoside. Reduced absorption when taken with cholestyramine, colestipol, mineral oil, orlistat. Ketoconazole.
Pregnancy Category Note
N/A
Adult Dose
Oral /IM:
Nutritional deficiency
Colecalciferol (Vitamin D3) is recommended 5-10 mcg
or 1-2ml (200-400 IU)/day
Osteoporosis
Prophylaxis and treatment
>50 years: 800-1000 IU (20-25 mcg) PO once daily with calcium supplements. May also be given via IM inj.
Hypoparathyroidism
50,000-200,000 IU (0.625-5 mg) PO once daily with calcium supplements. May also be given via IM inj.
Child Dose
Nutritional Supplementation
RDA
0-12 months: 400 IU (10 mcg) PO once daily
1-18 years: 600 IU (15 mcg) PO once daily
Vitamin D-Resistant Rickets
12,000-500,000 IU (0.3-12.5 mg) PO once daily
Familial Hypophosphatemia
40,000-80,000 IU (1-2 mg) PO once daily with phosphate supplements; may be reduced after stage of growth is complete
Renal Dose
N/A
Administration
May be taken with or without food.
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.